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Biopharmaceuticals make up a signiﬁcant proportion of medicinal products used for the treatment of
diseases such as cancer, arthritis, cardiac dysfunctions and AIDS. Access to therapies based on the use of
these products has been limited as a result of the high marketing costs. Cuba has a biopharmaceutical
industry with great potential for innovation, capable of developing new products and to produce others,
like the biosimilars destined to fulﬁll the needs of its National Health System. The Center for State Control
on the Quality of Drugs (CECMED) the Cuban NRA, is facing the challenge of regulating the approval of
biosimilar products manufactured locally. Consequently, CECMED has issued a position paper estab-
lishing the basic principles for regulation of these products and a speciﬁc guideline on this was
elaborated.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
Recombinant proteins and monoclonal antibodies represent
a signiﬁcant proportion of the medicinal products used for the treat-
ment of diseases such as cancer, arthritis, cardiac dysfunction andAIDS.
Access to therapies based on the use of biological products has
been limited, particularly in the third world countries, as a result of
the high costs stipulated by the pharmaceutical companies that
have developed and patented these products. The expiration of
patents and data protection for many of these products in the
coming years opens the opportunity for other manufacturers to
produce and market, with acceptable prices, new versions of the
innovator, facilitating the access to them, which in turn translates
into greater beneﬁt for patients. Therefore, it is imperative that
National Regulatory Authorities (NRA) adopt positions and estab-
lish the corresponding regulatory environment for these products.
Cuba has a biopharmaceutical industry capable of responding to
the increasingly rising needs of its National Health System. During
the last two decades, CECMED has faced the challenge of regulating
a national industry with a great scientiﬁc and high innovative
potential and now is dealing with the approval of biosimilar
products locally manufactured.537 271 4023.
ría Núñez).
ll rights reserved. The World Health2. National context
Highlydevelopedscienceparks (SP)haveplayedan important role in
the scientiﬁc and technology development. In many cases, like in Cuba,
these are scientiﬁc organizations that link science, manufacturing and
services altogether. This is particular relevant in the ﬁeld of the
biotechnology andmedical e pharmaceutical industry [1].
In the case of Cuba, the science park of western Havana (in
spanish “Polo Cientíﬁco del Oeste de La Habana”) was created as an
organizational unit in 1990. It brings together various institutions on
the basis of a strategy of a “closed loop”, covering all stages of
research, development, production and marketing of a product.
Some institutions work in a great diversity of areas (e.g. vaccines,
rDNA products, agricultural products, etc), others are more focused
on speciﬁc topics (e.g. molecular immunology) [1]. These institutions
possess trained and experienced staff, including scientists and health
professionals. The Center for Genetic Engineering and Biotechnology,
the Center for Molecular Immunology, the Finlay Institute are some
of the institutions of the science park of the western Havana.
For the last twenty years the science park of the western Havana
has sustained a growth in scientiﬁcetechnological activity, partic-
ularly from 1998. Different products have been developed and
introduced into the Cuban market, and also exported to others
countries. Most of them are medicinal products for human use,
such as vaccines, cytokines and monoclonal antibodies but culture
media, veterinary medicinal products, diagnostics and medicalOrganization has granted the Publisher permission for the reproduction of this article.
Y. Hechavarría Núñez et al. / Biologicals 39 (2011) 317e320318equipment are also included. But the main roles have been the
contribution to the control of infectious diseases, in the increase of
the life expectancy and in the reduction of infant mortality [2].
Up until October 2010, 133 biological products have been
licensed, of which 67 are locally manufactured. For locally produced
approved products, vaccines are the largest product type followed
by alfa interferon and blood derivatives, whilst for imported
products, insulins as well as pegylated compounds ranked ﬁrst,
followed by vaccines (Fig. 1) [3]. It should be highlighted that local
products are mostly produced by a unique manufacturer. However,
the same imported product is usually manufactured by more than
one company.
Monoclonal antibodies are an interesting case because there are
only 4 imported products (Mabthera rituximab, Herceptin trastu-
zumab, Avastin bevacizumab, Simulet basiliximab) and 1 locally
manufactured (CIMAher nimotuzumab) product approved [3].
However, cancer has been the second leading cause of death for the
whole Cuban population for more than three decades and the
leading cause of premature mortality [4,5]. Consequently health
authorities have allocated resources and efforts for patients
suffering from this disease. But in 2009, for instance, only the 64%,
15% and 5% of Mabthera, Herceptin and Avastin respectively, of the
real patient needs were imported, which is clearly insufﬁcient to
treat all patients reported in the country. For this reason, one of the
main objectives of the cancer control program is to expand local
production of products for oncology use (cytostatics, support
products and new biotechnology products) 3 [4] and the pipeline of
the science park of the western Havana for the next decade incor-
porates the production of cancer therapeutic vaccines and similar
monoclonal antibodies.
3. Regulatory framework in Cuba
The legal basis for marketing authorization of medicinal prod-
ucts is based on the Ministerial Resolution “Rules for MarketingFig. 1. Comparison between the number of local and imported licensed biological products
manufactured biologicals. For imported products, insulin and pegylated compounds ranked
(combination of products) and products obtained from human placenta, animal tissues.Authorization of Medicinal Products for Human Use” [6]. This
document sets up the classiﬁcation of medicinal products in
different categories according to their degree of novelty. Tradi-
tionally biological and biotechnological products were included in
category A, with the greatest degree of novelty.
After several years of implementation of these classiﬁcation
criteria, CECMED identiﬁed the need to redesign it, taking into
account the evidence at the level of quality, safety and efﬁcacy, as
well as the time the product has been in themarket and therapeutic
effect of the products. As a result, the rules for marketing autho-
rization were updated on 2009 and new classes and classiﬁcation
categories were deﬁned (Table 1). The new classiﬁcation categories
consider three basic concepts: the deﬁnition well delimited of two
classes of medicinal products: new and known; the period of use in
the international and/or national market of the medicinal product
and the inclusion of biological products within the class of known
medicinal products.
Moreover, the information to be submitted for marketing
authorization application is described in the Ministerial Resolution
“Requirements for Marketing Authorization, Renewal and Variation
Applications of Medicinal Products for Human Use” [7]. This
document is divided as follows: Information for Drugs and Infor-
mation for Biological/Biotechnological products. The volume of
data to be presented depends on the category of its classiﬁcation.
That is, for a category A product a full dossier is required for quality,
non-clinical and clinical information whereas for a category C
product, a reduced data package could be accepted particularly for
non-clinical and clinical information.
Most of the biological products were licensed on a basis of a full
dossier for quality, non-clinical and clinical data. Nevertheless some
products were approved considering comparability information for
non-clinical and/or clinical data. That is the case of a recombinant
erythropoietin locally manufactured, which was approved in 2004.
The application included information related to comparative
studies developed for non-clinical and clinical information using: by type of products vaccines, alfa interferon and blood derivatives are most for local
ﬁrst, followed by vaccines PEG-compounds: pegilated compounds Others: includes kits
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Y. Hechavarría Núñez et al. / Biologicals 39 (2011) 317e320 319EPREX, a product not licensed in Cuba as comparator, while for
quality a stand-alone approach was adopted.
Other guidelines concerning the development of stability
studies, validation of analytical assays and the characterization of
reference materials, amongst others, are available [8] because all
functions are covered by a regulatory system based on laws,
regulations, decisions and procedures. Additionally, recommen-
dations fromWHO, ICH and PARF network are also considered, as
well as some speciﬁc guidelines issued by FDA and EMA.lin
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a4. Similar biotherapeutic products
Regarding the products included on category C, there is
a particular case for biological products that claim to be similar to
an already approved biological product. In this case the term
known biological product instead biosimilar was adopted in Cuba,
as this term is deﬁned in our regulations. It was also taken into
account that biological products are considered molecules of
highly structural complexity and very sensitive to important
variations in their also complex manufacturing process. However,
despite of these facts, the scientiﬁc and technical advances in the
characterization of these molecules has allowed scientist moni-
toring and identiﬁying potential modiﬁcations in their molecular
structure. This may lead to a new approach when deﬁning new
and known biological products.
Although the rules for marketing authorization establish the
legal basis for the approval of known biological products, there is
not yet any biological product approved under this category. In
March, 2009 a position paper was issued, deﬁning the general
strategy to be followed for the approval of a known biological
product. A working group was also created, comprising NRA and
industry staff, charged with discussing scientiﬁc and regulatory
issues on known biological products. The main issues identiﬁed
were related to clinical trial design (equivalence vs non-inferiority
vs non-comparative); quality and non-clinical information
required for known biological products, particularly Mabs, and
whether the reference product must be licensed in Cuba and the
strategy to be adopted when it is not licensed in our country.
Speciﬁc guidelines were developed taking into account the
experience accumulated by CECMED, as a result of the evaluation
of applications for clinical trials and marketing authorizations of
the biological products approved in Cuba, the assessment of
comparability studies submitted due to manufacturing process
changes and non-clinical and clinical comparability studies con-
ducted in the country. The ﬁndings generated from the debate in
the working group were also considered.Table 1
Classiﬁcation categories for medicinal products established on the Rules for
Marketing Authorization.
Class 1. New Medicinal Product: Requires demonstration of quality,
safety and efﬁcacy and has been marketed for less than ﬁve years.
Are divided into two categories
Category A New molecular entity.
Category B New salt, ester, isomer, dosage form, administration
route, drug substances association.
Class 2. Known Medicinal Product: Requires demonstration of quality,
as well as elements of safety, efﬁcacy or therapeutic
equivalence, when applicable, and has been marketed for more
than ﬁve years. Are grouped into one category:
Category C Multisource medicinal products, including biological
products, which present the same drug substance,
dosage form, strength or concentration and indications
of other medicinal products, already licensed in Cuba
or another country.
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Y. Hechavarría Núñez et al. / Biologicals 39 (2011) 317e320320In general, the guideline took into account the following
principles:
- A full dossier is requested for quality, according to the
requirements for marketing authorization approval in force. An
additional section comprising all the information relating to
comparative studies conducted for the known biological
product with the biological reference product should be
submitted. This section will include data on the determination
of physicochemical, biological activity, immunological proper-
ties, purity and impurities and contaminants, and other tests
that could be considered necessary (e.g, pH and osmolality of
the ﬁnal product).
- The magnitude and complexity of non-clinical and clinical data
will depend on the existing knowledge about the biological
reference product, pharmacological classiﬁcation, the claimed
therapeutic indication as well as the differences detected
during the quality comparative characterization. Non-clinical
information should include results of comparative studies for
biological activity, bioavailability and single-dose toxicity
studies. Local tolerance and immunogenicity data will be also
requested.
- For the clinical data, a detailed analysis of safety studies re-
ported for the biological reference product and those con-
ducted for the known biological product should be presented.
Also, results of efﬁcacy clinical trials should be included; the
design of this can be equivalence, non-inferiority or non-
comparative, but the choice should be justiﬁed. A non-
comparative study is an exceptional case, for molecules like
monoclonal antibodies, where a comparative trial might be not
feasible due to heterogeneity in the response of the patient
populationwould require a higher number of patients to prove
similarity. This choice will be analyzed case-by-case. All clinical
trials carried out for the known biological product to support
the marketing authorization application should be previously
authorized by CECMED.
- A speciﬁc section of information is added for similar monoclonal
antibodies, given particular characteristics of these molecules.
- A risk management program/active post-marketing surveil-
lance plan should be also presented.
- The Reference Biological Product should be licensed based on
full quality, safety, and efﬁcacy data. This product should
preferably be approved in Cuba. However, as Cuba is a country
with a small market, it is possible that the RBP may not be
licensed. In this case, the applicant has two choices: select
a product licensed in countries with experience in
manufacturing, control, regulation and post-marketing
surveillance activities for biological/biotechnological products
or a product authorized by NRAs of the region of Americas thathas passed the evaluation process carried out by PAHO (these
are NRAs that has been considered “matured” in the regulation
and control of biological/biotechnological products). The
rationale for RBP selection should always be presented.
Some general principles established in the WHO guidelines for
similar biotherapeutic products [9] were considered. However,
there are some differences between the WHO and the Cuban
guidelines (Table 2).
The ﬁrst draft of the Cuban guidelinewas released for regulatory
consultation during October and November 2010 [10]. It is expected
to have the ﬁnal document approved during the ﬁrst semester of
2011.
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